Featured Research

from universities, journals, and other organizations

Peptide Vaccine Can Produce Complete Remission In Myeloid Leukemia Patients

Date:
December 17, 2004
Source:
University Of Texas M. D. Anderson Cancer Center
Summary:
Researchers from The University of Texas M. D. Anderson Cancer Center are reporting the first study to show that vaccination with a peptide that is abnormally expressed on myeloid leukemia cells can produce a complete molecular remission in some patients.

SAN DIEGO - Researchers from The University of Texas M. D. Anderson Cancer Center are reporting the first study to show that vaccination with a peptide that is abnormally expressed on myeloid leukemia cells can produce a complete molecular remission in some patients.

The experimental vaccine produced an immune response in 60 percent of patients tested - or 20 of 33 evaluable patients, according to their study, which is being presented at the annual meeting of the American Society of Hematology.

Of those 20 patients who mounted an immune response against their cancer, 14 had an overall survival of four years, and none of the 13 patients who did not have such a response lived that long, they say. Three patients are in "molecular remission" in which there is no evidence of the disease remaining.

"These are very promising results in a group of patients who were quite sick, and who normally would live for just months," says the study's lead investigator, Jeffrey Molldrem, M.D., an associate professor in the Department of Blood & Marrow Transplantation.

"Not only can we say that some of these patients had an immune response, but they also went into remission, and that has never been demonstrated to occur after peptide vaccination before. And for patients who showed an immune response but did not go into remission, progression of their cancer was slowed down compared to patients who did not have an immune response to the vaccine," he says. "Of course, we have much more research to do, especially in testing greater numbers of patients within each disease group."

Nearly all of these patients had either active or relapsed acute myelogenous leukemia (AML) or refractory chronic myelogenous leukemia (CML) - forms of leukemia in which there is a dangerous accumulation of immature cells in the bone marrow - or they had high-risk myelodysplastic syndrome (MDS), a precancerous bone marrow disorder.

The vaccine is made from the PR1 peptide, a small part of a protein found on the inside of leukemia cells. Delivery of the vaccine induces immune cells that recognize the PR1 peptide, which are recruited to the bone marrow that contains leukemia," says Molldrem. "The PR1 peptide is naturally present in normal bone marrow cells and since the target protein is overexpressed on leukemia cells, it directs immune T-cells to kill the leukemia and leave normal cells alone."

Like many vaccines used to induce immunity against infections, this one appears to create an immune system "memory" for the PR1 peptide, conferring long-lasting protection. "Patients only get the vaccine three times, yet we have been able to measure an immune response in patients four years after treatment," says Molldrem.


Story Source:

The above story is based on materials provided by University Of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas M. D. Anderson Cancer Center. "Peptide Vaccine Can Produce Complete Remission In Myeloid Leukemia Patients." ScienceDaily. ScienceDaily, 17 December 2004. <www.sciencedaily.com/releases/2004/12/041206205351.htm>.
University Of Texas M. D. Anderson Cancer Center. (2004, December 17). Peptide Vaccine Can Produce Complete Remission In Myeloid Leukemia Patients. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2004/12/041206205351.htm
University Of Texas M. D. Anderson Cancer Center. "Peptide Vaccine Can Produce Complete Remission In Myeloid Leukemia Patients." ScienceDaily. www.sciencedaily.com/releases/2004/12/041206205351.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins